Publisher Correction: Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial

Correction to: Nature Medicine 10.1038/s41591-024-03261-7, published online 13 September 2024.

In the version of this article initially published, members of the DESTINY-Breast12 study group were not included by the journal in the full text. In Table 1, under the “Prior CNS therapies n (%)” section, seven rows have been added, in addition to the original CNS radiotherapy, WBRT and SRS rows. In Table 1 and in the Results: Patients section, “intracranial therapy” has been amended to “CNS radiotherapy,” while the text “the type of intracranial radiotherapy was not always recorded by investigators, and only WBRT and SRS intracranial radiotherapy were reported” has been removed. All changes appear in the HTML and PDF versions of the article.